CellaVision AB (CLVSF) Price & Analysis

CellaVision AB released its earnings results on Feb 05, 2026. The company reported $0.199 earnings per share for the quarter, beating the consensus estimate of $0.145 by $0.054.

Is CellaVision AB overvalued?

According to Wall Street analysts CellaVision AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CellaVision AB pay dividends?

CellaVision AB pays a Annually dividend of $0.263 which represents an annual dividend yield of 1.37%. See more information on CellaVision AB dividends here

What is CellaVision AB’s EPS estimate?

CellaVision AB’s EPS estimate is 0.18.

How many shares outstanding does CellaVision AB have?

CellaVision AB has 23,851,547 shares outstanding.

What happened to CellaVision AB’s price movement after its last earnings report?

CellaVision AB reported an EPS of $0.199 in its last earnings report, beating expectations of $0.145. Following the earnings report the stock price went up 2.589%.

Which hedge fund is a major shareholder of CellaVision AB?

Currently, no hedge funds are holding shares in CLVSF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CellaVision AB

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

CellaVision AB (CLVSF) Earnings & Revenues

Historic Earnings Reports

CLVSF Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presents a broadly positive operational and financial picture: solid revenue and organic growth, a strong EBITDA margin above target, record Americas performance, important strategic progress (bone marrow CE Mark, software validation, DI-60 throughput improvements), a healthy cash position and a proposed dividend increase. Offsetting factors include a weak APAC quarter driven by comparables and tender timing, softness in reagents/software mix that pressured Q4 gross margin, FX headwinds, and near-term uncertainty on revenue ramp from new product launches (bone marrow and U.S. methanol-free reagents). Overall these negatives appear manageable against the company’s clear commercial momentum and strategic milestones.View all CLVSF earnings summaries